Samir Dabbous, MD
Cardiovascular Disease · Dearborn, MINPI 1538195664
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,815 of the $6,341 with a category attached, or 75.9%. 26 manufacturers reported payments, led by Edwards Lifesciences at 33.6% of the total. Reporting peaked in 2019 at $2,332 and has fallen 76.0% since, to $559 in 2025.
Across 191 payments — averaging $33.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Amgen$568
- E.r. Squibb & Sons, L.L.C.$407
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$391
- Abiomed$305
- Boehringer Ingelheim$276
- plus $2K from 20 others
Across 1 payment — averaging $950.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$950
What the payments were for
- Speaking & faculty fees$1,50024%
- Travel & lodging$120%
- Food & beverage$4,81576%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 19 | $2,128 |
| Amgen | 29 | $568 |
| E.r. Squibb & Sons, L.L.C. | 29 | $407 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $391 |
| Abiomed | 3 | $305 |
| Boehringer Ingelheim | 13 | $276 |
| Merck | 14 | $271 |
| Boston Scientific | 2 | $258 |
| Heartflow, Inc. | 4 | $235 |
| AstraZeneca | 16 | $233 |
| Abbott | 2 | $178 |
| Cardiva Medical, Inc. | 5 | $176 |
| Chiesi USA, Inc. | 7 | $151 |
| Novartis | 7 | $126 |
| Johnson & Johnson | 7 | $121 |
| Novo Nordisk | 5 | $116 |
| Pfizer | 5 | $85 |
| Medtronic | 1 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $70 |
| Cardinal Health 200 LLC | 2 | $35 |
| Amarin Pharma, Inc. | 2 | $31 |
| ZOLL Circulation Inc | 2 | $30 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Cordis US CORP. | 1 | $19 |
| Teleflex LLC | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,618
- Impella$278
- SAPIEN 3 Ultra RESILIA$261
- FFRct$162
- COROFLOW$162
- SYNERGY$156
- COMET$102
How this compares
$6,341 in reported general payments places this provider in the 65th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 220 | $236,579 |
| JardianceEmpagliflozin | 88 | $91,828 |
| FarxigaDapagliflozin Propanediol | 64 | $54,399 |
| XareltoRivaroxaban | 39 | $46,733 |
| Repatha SureclickEvolocumab | 55 | $36,903 |
| EntrestoSacubitril/Valsartan | 23 | $34,410 |
| BrilintaTicagrelor | 34 | $26,765 |
| Metoprolol Succinate | 531 | $7,701 |
| Praluent PenAlirocumab | 14 | $6,703 |
| ClopidogrelClopidogrel Bisulfate | 420 | $6,597 |
| Amlodipine Besylate | 533 | $4,623 |
| Losartan Potassium | 303 | $4,487 |
| Atorvastatin Calcium | 276 | $3,173 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 236 | $3,109 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 14 | $3,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $236,579220 claims |
| Boehringer IngelheimJardiance | $276 | $91,82888 claims |
| AstraZenecaFarxiga, Brilinta | $233 | $81,16598 claims |
| Johnson & JohnsonXarelto | $121 | $46,73339 claims |
| NovartisEntresto | $126 | $34,41023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Elias KassabDearborn$172K
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.